Differential Expression of MicroRNAs in GH-secreting Pituitary Adenomas

Overview

Journal Diagn Pathol

Publisher Biomed Central

Specialty Pathology

Date 2010 Dec 9

PMID 21138567

Citations 37

Authors

Zhi-Gang Mao

Dong-Sheng He

Jing Zhou

Bin Yao

Wei-wei Xiao

Chun-Hua Chen

Yong-Hong Zhu

Hai-Jun Wang

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this study was to (1) identify specific miRNAs in growth hormones (GH)-secreting pituitary adenomas; (2) determine the relationship between the expression of these miRNAs and tumor size, somatostatin analogs treatment, and responsiveness to somatostatin analogs (SSA).

Methods: Fifteen GH-secreting adenomas patients were treated with lanreotide for 4 months before surgery. Patients with 50% reduction of GH secretion by lanreotide were considered as SSA responders, while patients with less than 50% of GH reduction were considered as SSA nonresponders. We analyzed the miRNAs in 21 GH-secreting pituitary adenomas and 6 normal pituitaries by miRCURY™ LNA array and some differentially expressed miRNAs were validated by quantitative real-time PCR.

Results: Fifty-two miRNAs were differentially expressed between GH-secreting pituitary adenomas and normal pituitaries. Differential expression of 9 miRNAs was observed between micro- and macro-adenomas. Thirteen miRNAs were differentially expressed between tumor samples from lanreotide-treated patients and those from lanreotide-untreated patients. Seven miRNAs were differentially expressed between SSA responders or GH nonresponders. Several identified miRNAs may be involved in cell proliferation, apoptosis, cancer development and progression.

Conclusions: Our results indicate that altered miRNAs expression is involved in GH-secreting pituitary adenomas transformation, which will shed light on the mechanisms for the treatment of acromegaly by SSA. Identification and characterization of the targets of altered miRNAs genes may elucidate molecular mechanisms involved in the pathogenesis of pituitary adenoma.

Citing Articles

miR-617 interacts with the promoter of and positively regulates its expression: implications for cancer therapeutics.

Sarkar N, Mishra R, Gopal C, Kumar A Front Oncol. 2024; 14:1411539.

PMID: 38939334 PMC: 11208480. DOI: 10.3389/fonc.2024.1411539.

Multiomics Approach to Acromegaly: Unveiling Translational Insights for Precision Medicine.

Kim K, Ku C, Lee E Endocrinol Metab (Seoul). 2023; 38(5):463-471.

PMID: 37828709 PMC: 10613768. DOI: 10.3803/EnM.2023.1820.

Exosomal RNAs in the development and treatment of pituitary adenomas.

Chang M, Jiang S, Guo X, Gao J, Liu P, Bao X Front Endocrinol (Lausanne). 2023; 14:1142494.

PMID: 36875488 PMC: 9981947. DOI: 10.3389/fendo.2023.1142494.

miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.

Henriques D, Lyra Miranda R, Dezonne R, Wildemberg L, Camacho A, Chimelli L Int J Mol Sci. 2023; 24(3).

PMID: 36769196 PMC: 9918086. DOI: 10.3390/ijms24032875.

The cAMP-signaling cancers: Clinically-divergent disorders with a common central pathway.

Bolger G Front Endocrinol (Lausanne). 2022; 13:1024423.

PMID: 36313756 PMC: 9612118. DOI: 10.3389/fendo.2022.1024423.

References

Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L . Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab. 2001; 86(1):140-5. DOI: 10.1210/jcem.86.1.7099. View

Reinhart B, Slack F, Basson M, Pasquinelli A, Bettinger J, Rougvie A . The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000; 403(6772):901-6. DOI: 10.1038/35002607. View

Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V . MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007; 14(3):791-8. DOI: 10.1677/ERC-07-0129. View

Stefani G, Slack F . Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol. 2008; 9(3):219-30. DOI: 10.1038/nrm2347. View

Esquela-Kerscher A, Slack F . Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-69. DOI: 10.1038/nrc1840. View

Kloosterman W, Plasterk R . The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006; 11(4):441-50. DOI: 10.1016/j.devcel.2006.09.009. View

Calin G, Croce C . MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006; 66(15):7390-4. DOI: 10.1158/0008-5472.CAN-06-0800. View

Yu J, Ryan D, Getsios S, Oliveira-Fernandes M, Fatima A, Lavker R . MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia. Proc Natl Acad Sci U S A. 2008; 105(49):19300-5. PMC: 2587229. DOI: 10.1073/pnas.0803992105. View

Plockinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S . Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab. 2008; 93(4):1203-10. DOI: 10.1210/jc.2007-1986. View

10.

Shimon I, Cohen Z, Ram Z, Hadani M . Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery. 2001; 48(6):1239-43; discussion 1244-5. DOI: 10.1097/00006123-200106000-00008. View

11.

Nilsen T . Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet. 2007; 23(5):243-9. DOI: 10.1016/j.tig.2007.02.011. View

12.

Heath K, Argente J, Barrios V, Pozo J, Diaz-Gonzalez F, Martos-Moreno G . Primary acid-labile subunit deficiency due to recessive IGFALS mutations results in postnatal growth deficit associated with low circulating insulin growth factor (IGF)-I, IGF binding protein-3 levels, and hyperinsulinemia. J Clin Endocrinol Metab. 2008; 93(5):1616-24. DOI: 10.1210/jc.2007-2678. View

13.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

14.

Bottoni A, Zatelli M, Ferracin M, Tagliati F, Piccin D, Vignali C . Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. J Cell Physiol. 2006; 210(2):370-7. DOI: 10.1002/jcp.20832. View

15.

Hofland L, van der Hoek J, Van Koetsveld P, de Herder W, Waaijers M, Sprij-Mooij D . The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004; 89(4):1577-85. DOI: 10.1210/jc.2003-031344. View

16.

Guo C, Sah J, Beard L, Willson J, Markowitz S, Guda K . The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer. 2008; 47(11):939-46. PMC: 2739997. DOI: 10.1002/gcc.20596. View

17.

Amaral F, Torres N, Saggioro F, Neder L, Machado H, Silva Jr W . MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. J Clin Endocrinol Metab. 2008; 94(1):320-3. DOI: 10.1210/jc.2008-1451. View

18.

Pasquinelli A, Reinhart B, Slack F, Martindale M, Kuroda M, Maller B . Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000; 408(6808):86-9. DOI: 10.1038/35040556. View

19.

Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, DeAngelis T, Baserga R . Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem. 2007; 282(45):32582-90. DOI: 10.1074/jbc.M702806200. View

20.

Johnson C, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D . The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007; 67(16):7713-22. DOI: 10.1158/0008-5472.CAN-07-1083. View